Peripheral Arterial Disease Trial, Recruiting (NCT04648462)

Peripheral Arterial Disease Trial, Recruiting NCT04648462 Sponsor: Maastricht Radiation Oncology Condition: Peripheral Arterial Disease

Printed from Voxsanity (voxsanity.com.au) — NCT04648462 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Arterial Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with a brain tumor that has a generally favorable outlook, where the median survival is expected to be more than 10 years
People aged 18 years or older
People who are in good general health and able to carry out normal daily activities, as measured by standard medical scoring tools (confirm with trial site)
People with no, or only very minimal, difficulties with thinking, memory, or cognition
People whose brain scans show that proton therapy would provide a meaningful dosing advantage over standard radiation therapy, specifically at least 5% less radiation to certain areas of the brain (confirm with trial site)
People who have given their informed consent to participate in the trial

Who may not be able to join:

People who are not suitable candidates for chemotherapy
People whose situation is considered suitable for stereotactic radiotherapy (a specific type of precisely targeted radiation treatment)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Danielle Eekers, Maastro Clinic, The Netherlands

Phone: +31884455600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04648462

Sponsor: Maastricht Radiation Oncology

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Arterial Disease

Trial contact: +31884455600

More information: https://clinicaltrials.gov/study/NCT04648462

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with a brain tumor that has a generally favorable outlook, where the median survival is expected to be more than 10 years
People aged 18 years or older
People who are in good general health and able to carry out normal daily activities, as measured by standard medical scoring tools (confirm with trial site)
People with no, or only very minimal, difficulties with thinking, memory, or cognition
People whose brain scans show that proton therapy would provide a meaningful dosing advantage over standard radiation therapy, specifically at least 5% less radiation to certain areas of the brain (confirm with trial site)
People who have given their informed consent to participate in the trial

Who may not be able to join:

People who are not suitable candidates for chemotherapy
People whose situation is considered suitable for stereotactic radiotherapy (a specific type of precisely targeted radiation treatment)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Maastricht Radiation Oncology

Registry

ClinicalTrials.gov

Start date

1 January 2018

Est. completion

1 January 2030

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Neurocognitive failure at 5 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov